These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 1657857)
21. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies. Grillon A; Schramm F; Kleinberg M; Jehl F PLoS One; 2016; 11(6):e0156690. PubMed ID: 27257956 [TBL] [Abstract][Full Text] [Related]
22. Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates. Doebbeling BN; Pfaller MA; Bale MJ; Wenzel RP Eur J Clin Microbiol Infect Dis; 1990 Apr; 9(4):298-301. PubMed ID: 2112467 [TBL] [Abstract][Full Text] [Related]
23. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. Aubert G; Pozzetto B; Dorche G J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371 [TBL] [Abstract][Full Text] [Related]
24. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Visser MR; Rozenberg-Arska M; Beumer H; Hoepelman IM; Verhoef J Antimicrob Agents Chemother; 1991 May; 35(5):858-68. PubMed ID: 1854167 [TBL] [Abstract][Full Text] [Related]
25. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents. McCarter YS; Mazens-Sullivan MF; Bartlett RC Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507 [TBL] [Abstract][Full Text] [Related]
26. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Dalhoff A; Petersen U; Endermann R Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575 [TBL] [Abstract][Full Text] [Related]
27. In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia. García-Rodríguez JA; García Sánchez JE; Muñoz Bellido JL; García Sánchez E; García García MI J Chemother; 1991 Jun; 3(3):143-6. PubMed ID: 1919651 [TBL] [Abstract][Full Text] [Related]
28. In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients. Akaniro JC; Stutman HR; Arguedas AG; Vargas OM Antimicrob Agents Chemother; 1992 Feb; 36(2):255-61. PubMed ID: 1318674 [TBL] [Abstract][Full Text] [Related]
29. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin. Pankuch GA; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1994 Feb; 38(2):369-70. PubMed ID: 8192468 [TBL] [Abstract][Full Text] [Related]
31. Activity of 4-quinolones against Pseudomonas aeruginosa. Morissey I; Smith JT Arzneimittelforschung; 1994 Oct; 44(10):1157-61. PubMed ID: 7818593 [TBL] [Abstract][Full Text] [Related]
32. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. Isenberg HD; Alperstein P; France K Diagn Microbiol Infect Dis; 1999 Feb; 33(2):81-6. PubMed ID: 10091030 [TBL] [Abstract][Full Text] [Related]
33. Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis. Millar BC; McCaughan J; Rendall JC; Moore JE Clin Respir J; 2021 Jan; 15(1):116-120. PubMed ID: 32790958 [TBL] [Abstract][Full Text] [Related]
34. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Thomson KS; Sanders CC; Hayden ME Antimicrob Agents Chemother; 1991 Nov; 35(11):2329-34. PubMed ID: 1804005 [TBL] [Abstract][Full Text] [Related]
35. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317 [TBL] [Abstract][Full Text] [Related]
36. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods. Biedenbach DJ; Croco MA; Barrett TJ; Jones RN Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):428-31. PubMed ID: 10442421 [TBL] [Abstract][Full Text] [Related]
37. The in-vitro activity of temafloxacin compared with other antimicrobial agents. King A; Bethune L; Phillips I J Antimicrob Chemother; 1991 Jun; 27(6):769-79. PubMed ID: 1657855 [TBL] [Abstract][Full Text] [Related]
38. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa. Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499 [TBL] [Abstract][Full Text] [Related]
39. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. Zhang L; Li XZ; Poole K J Antimicrob Chemother; 2001 Oct; 48(4):549-52. PubMed ID: 11581236 [TBL] [Abstract][Full Text] [Related]
40. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Child J; Andrews J; Boswell F; Brenwald N; Wise R J Antimicrob Chemother; 1995 Jun; 35(6):869-76. PubMed ID: 7559198 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]